AstraZeneca And Merck's Lynparza Delays Ovarian Cancer Progression

10:16 EDT 27 Jun 2018 | Pharmaceutical Processing

News
Women with BRCA-mutated (BRCAm) advanced ovarian cancer treated first-line with Lynparza maintenance therapy had a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo.
Contributed Author: 
Merck
Topics: 

Original Article: AstraZeneca And Merck's Lynparza Delays Ovarian Cancer Progression

More From BioPortfolio on "AstraZeneca And Merck's Lynparza Delays Ovarian Cancer Progression"